No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
www.ocumension.comNo one on the platform currently holds 1477.HK.
No tracked institution reports a position in 1477.HK as of their last filing.
No one on the platform has traded 1477.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 92.7% | 127.9% | ||||
| Profit Margin % | -19.7% | -190.9% | ||||
| Free Cash Flow Margin % | -44.6% | -443.5% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +41.7% | $-0.01 | $-0.01–$-0.01 | — | 1 |
| 2027 | $1.5B | +28.4% | $0.08 | $0.07–$0.09 | — | 1 |
| 2028 | $1.9B | +28.1% | $0.33 | $0.29–$0.36 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-28 | $-0.03 | $-0.14 | -300.0% |
| 2026-03-26 | $-0.08 | $-0.04 | +42.8% |
| 2025-08-21 | $-0.13 | $-0.19 | -41.7% |
| 2025-03-31 | $-0.19 | $-0.17 | +9.4% |
| 2024-08-12 | $-0.23 | $-0.25 | -9.3% |
| 2024-03-22 | $-0.31 | $-0.29 | +5.6% |
| 2023-08-25 | $-0.35 | $-0.35 | -0.8% |
| 2023-03-31 | $-0.38 | $-0.37 | +2.6% |
| $2.09 |
| -1.18% |
| $5.6B |
| — |
| 2172.HKMicroPort NeuroTech Limited | $8.05 | +0.00% | $4.7B | — |
| 2273.HKGushengtang Holdings Limited | $27.08 | +0.07% | $5.7B | — |
Source: Financial Modeling Prep · peers by sector/industry